• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Competitor Analysis: CHK and KSP/Eg5 Inhibitors Product Image

Competitor Analysis: CHK and KSP/Eg5 Inhibitors

  • Published: August 2009
  • Region: World
  • 19 Pages
  • La Merie Publishing

The present Competitive Intelligence Report about checkpoint kinase (CHK) and kinesin spindle protein (KSP) or Eg5 inhibitors provides a competitor evaluation in the field of novel molecular entities inhibiting CHK or KS/Eg5 for treatment of cancer as of August 2009. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Progression through the cell cycle is monitored by surveillance mechanisms known as cell cycle checkpoints. Dysfunction in cell cycle checkpoints leads to genomic instability and contributes to tumor progression. Checkpoint kinase 1 (CHK-1) plays a critical role in the activation of mitotic spindle checkpoint and DNA damage checkpoint. CHK-1) has become an oncology target of significant current interest. Inhibition of CHK-1 abrogates DNA damage-induced cell cycle checkpoints and might provide therapeutic benefit. At least seven different checkpoint kinase inhibitors are in early clinical development to evaluate its role in cancer therapy. READ MORE >

Index:

- CHK Inhibitors

- E2F Pathway modulators

- KSP/Eg5 Inhibitors

- Corporate CHK and KSP/Eg5 Inhibitor R&D Pipelines

- About La Merie

Format Properties
Electronic (PDF) The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.
Site License The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.
Enterprisewide The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.
Note: Product cover images may vary from those shown
More

RELATED PRODUCTS

Our Clients

Our clients' logos